Srini Ramanathan
Corporate Officer/Principal presso ROIVANT SCIENCES LTD.
Profilo
Srini Ramanathan is currently the Chief Development Officer at Roivant Sciences Ltd.
Prior to this, he worked as the Senior VP-Research & Development Sciences at Horizon Therapeutics Plc.
He holds a doctorate degree from Rutgers State University of New Jersey and a graduate degree from Duquesne University School of Law.
Posizioni attive di Srini Ramanathan
| Società | Posizione | Inizio |
|---|---|---|
| ROIVANT SCIENCES LTD. | Corporate Officer/Principal | 02/05/2022 |
Precedenti posizioni note di Srini Ramanathan
| Società | Posizione | Fine |
|---|---|---|
| HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Corporate Officer/Principal | - |
Formazione di Srini Ramanathan
| Duquesne University School of Law | Graduate Degree |
| Rutgers State University of New Jersey | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| ROIVANT SCIENCES LTD. | Health Technology |
| Aziende private | 1 |
|---|---|
Horizon Therapeutics Plc
 Horizon Therapeutics Plc Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. | Health Technology |
- Borsa valori
- Insiders
- Srini Ramanathan
